Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 14 August 1992:
Vol. 257. no. 5072, pp. 915 - 918
DOI: 10.1126/science.1502558
Prev | Table of Contents | Next

Articles

Science, Vol 257, Issue 5072, 915-918
Copyright © 1992 by American Association for the Advancement of Science

articles

Patents on random complementary DNA fragments?

TD Kiley

The proposal by the National Institutes of Health (NIH) to patent products resulting merely from sequencing the human genome is a mistake: at worst, it is wrong in patent law; at best, it relies on deficiencies in law concerning what is "useful" as a requirement for patents. The proposal is symptomatic of a problem besieging biotechnology--attempts to control the raw material of scientific experimentation before research has determined the practical value of such material--that needs curing on many fronts. Corrective measures are proposed for adoption by the Executive branch, the Congress, and the courts.




ADVERTISEMENT
Click Me!

ADVERTISEMENT

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)